UnknownPhase 1NCT05765006
CD19-CART(Relma-cel) for Moderate to Severe Active Systemic Lupus Erythematosus
Studying Pediatric systemic lupus erythematosus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Shanghai Ming Ju Biotechnology Co., Ltd.
- Principal Investigator
- yu HuUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Intervention
- Relma-cel(biological)
- Enrollment
- 24 target
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2023 – 2025
Study locations (1)
- Relma-cel Medical, Shanghai, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05765006 on ClinicalTrials.govOther trials for Pediatric systemic lupus erythematosus
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07425730Early Myocardial Dysfunction Helps Identify Severe Refractory Pediatric LupusShanghai Jiao Tong University School of Medicine
- RECRUITINGEARLY PHASE1NCT07339332A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus ErythematosusUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE1NCT07109986UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus NephritisNanjing IASO Biotechnology Co., Ltd.
- ACTIVE NOT RECRUITINGNANCT07196072A Multi-component, Person-centered, and Yoga-based Coaching Program for Lupus Chronic PainUniversity of Michigan
- RECRUITINGNCT07128966Direct to Patient Minimal Risk Biospecimen and Data Collection ResearchJoined Bio
- RECRUITINGNCT06659029Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab UsersAstraZeneca
- RECRUITINGPHASE1NCT06613360A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus ErythematosusCullinan Therapeutics Inc.
- RECRUITINGNCT07017868Correlation Between Serum Uric Acid, Serum Homocysteine Level and Interleukin- 17 in Lupus Nephritis PatientsSohag University